Gain Therapeutics Q1 net loss $0.16/share; Phase 1b of GT-02287 enrollment underway

Gain Therapeutics, Inc.

2025-Q1 EPS reported -$0.16

Net loss per share $0.16 (basic/diluted) vs $0.22 prior year; cash $9.1M as of March 31, 2025.
R&D expenses $2.3M (down $0.2M), G&A expenses $2.1M (up $0.2M) compared to Q1 2024.
Phase 1b study of GT-02287 for Parkinson's disease initiated; first biomarker analysis expected mid-2025.
Gene Mack appointed CEO effective Jan 6, 2025; Gianluca Fuggetta assumed SVP Finance and PFO role.
IND submission to FDA expected by year end 2025; Phase 1b completion expected Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.